From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Videos|June 1, 2015
Advice for Pharmacy Students About to Graduate
Shaun Ellen Gleason, PharmD, MGS, assistant professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, gives advice to pharmacy students graduating this year.
Advertisement
Shaun Ellen Gleason, PharmD, MGS, director of Distance Degrees and Programs, iPharmD, and assistant professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, gives advice to pharmacy students graduating this year.
This video was recorded at APhA's Annual Meeting and Exposition in March 2015.
Advertisement
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
3
Earlier PRRT in Neuroendocrine Tumors Puts Pharmacists at the Center of Coordination
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5